10 domestic and multinational pharmaceutical companies jumped into the development of Humira biosimilar
With the patent expiration of AbbVie's 'Humira' ahead, 10 domestic and multinational pharmaceutical companies are jumping into development of Humira biosimilar.
Humira records annual domestic sales of 45 billion won and accounts for 30% of global rheumatoid arthritis therapeutics market. Therefo...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
